Experiência em 12 casos de melanoma com anticorpos monoclonais

• Autor(a) principal: Silva , Amaury Barbosa da
• Data de Publicação: 2023
• Outros Autores: Calegaro, José Ulisses M., Marcelino, Nivaldo, Gomes, Ênio de Freitas, Carvalho, Antonio Carlos Macedo de, Pinheiro, Ely dos Santos
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/2993
• topic: Melanoma; Anticorpos Monoclonais; Estadiamento; Seguimento; Melanoma; Monoclonal Antibodies; Staging; Follow-Up

The authors present the results of scintigraphyc study in 12patients with melanoma. The twelve patients, eight males, nine white and three black, with a median age of 51.5 years old, with melanoma in varioussites, weredividedin twogroups: Grupo 1 - five cases, for disease staging; Group II – seven cases, for disease follow-up. The scintigraphyc study was realized 2, 6, 10 and 24 hours after endovenous injection of 50mCi (185OMBq) labelling monoclonal antibodies anti-melanoma (Tecnemab from Sorin). The studies were use full in detecting lesions: skin (5x); Iymphnodes (4x). Ocular, brain and soft tissues one time each independent of the scintigraphy objective (if staging or follow-up). Conclusions: 1 – little differences in concentra tion must be take in mmd; 2- the whole body study is necessary; 3- the routine must use a precocious (2-4 hours) anda tardious study (12-24 h); 4- lung metastasis are not detected often.